Paper Details

  1. Home
  2. Paper Details

Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients.

Author: , BergerDan, ChiliadePhilippe, ColsonAmy, ConantMarcus, GallantJoel, HaubrichRichard, LefebvreEric, NadlerJeffrey, PieroneGerald, SaagMichael, WilkinTimothy, van BaelenBen

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

TMC114/r treatment resulted in greater virological and immunological responses in ART-experienced patients compared with CPI at 24 weeks.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Agents for the treatment of HIV-1-infected patients with resistance to current antiretroviral (ART) drugs are needed. METHODS: TMC114-C202 was a randomized, partially blinded, dose-finding study in treatment-experienced HIV-1-infected patients with one or more primary protease inhibitor...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/17413685

データ提供：米国国立医学図書館（NLM）

Fighting HIV: A New Weapon in the Arsenal

The battle against

HIV

is a constant struggle, and researchers are always searching for new weapons in the arsenal to combat this relentless foe. This research explores the efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. The authors conducted a clinical trial to evaluate the effectiveness of this drug combination in patients who had developed resistance to other antiretroviral therapies. They found that [主要な発見] This research offers a promising new treatment option for HIV patients who have developed resistance to current therapies.

Hope for Treatment-Experienced HIV Patients

The study's findings provide a glimmer of hope for treatment-experienced HIV patients, who often face limited treatment options. TMC114/ritonavir demonstrated significant virological and immunological benefits, suggesting a potential new avenue for managing HIV in patients with drug resistance. This research represents a significant step forward in the ongoing quest to develop effective treatments for HIV.

Navigating the Desert of HIV Treatment

Navigating the desert of HIV treatment can be challenging, but researchers are constantly searching for new oases of hope and effective therapies. This research reinforces the importance of continued exploration and innovation in the field of HIV treatment. By understanding the mechanisms underlying drug resistance and developing new treatment approaches, we can provide better care for individuals living with HIV and move closer to a world without AIDS.

Dr.Camel's Conclusion

The battle against HIV is a long and arduous one, but this research offers a beacon of hope for treatment-experienced patients. TMC114/ritonavir demonstrates a potential for significant virological and immunological benefits, offering a new weapon in the arsenal against this relentless foe. This research underscores the importance of ongoing research and innovation in the quest for effective treatments for HIV.

Date :
  1. Date Completed 2007-08-06
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

17413685

DOI: Digital Object Identifier

00002030-200703300-00002

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.